Outcome Of Hibiscus Sabdariffa (Zobo) And Hyphaene Thebaica ( Goriba) on High Blood Pressure Among Humans with High Blood Pressure In Murtala Muhammad Special Hospital Kano-North-Western Nigeria
Phase 1
Recruiting
- Conditions
- Cardiology
- Registration Number
- PACTR202312830900344
- Lead Sponsor
- Tertiary Education Fund
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Patient with Grade 1 high blood pressure
Patient within the age range of 45 to 65 years
Patient with Grade 1 high blood pressure without co-morbidity
Exclusion Criteria
Patient with high blood pressure in Grade II and above
Patient with high blood pressure with co-morbidity
Patient with high blood pressure but with age range greater than 65 years
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the antihypertensive effects of Hibiscus Sabdariffa and Hyphaene Thebaica in clinical trials?
How does the combination of Hibiscus Sabdariffa and Hyphaene Thebaica compare to standard antihypertensive therapies in efficacy and safety profiles?
Are there specific biomarkers that can predict patient response to Hibiscus Sabdariffa and Hyphaene Thebaica in managing hypertension?
What are the potential adverse events associated with Hibiscus Sabdariffa and Hyphaene Thebaica treatment in phase I trials for hypertension?
What drug classes or compounds are being investigated alongside Hibiscus Sabdariffa and Hyphaene Thebaica for hypertension management in preclinical or clinical studies?